Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29852620 | 0.88 | MAPT (0.54) | CYP3A4MAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL2087722 | 0.88 | MAPT (0.54) | CYP3A4MAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL13166532 | 0.82 | CYP3A4 (0.47) | CYP3A4MAPTKDM4ELMNAAXL | |
| SCHEMBL3825162 | 0.80 | CYP3A4 (0.49) | CYP3A4MAPTKDM4ELMNASMN1; SMN2 | |
| Imidazole SCHEMBL144265 | 0.77 | CYP3A4 (0.42) | CYP3A4MAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL18416512 | 0.76 | LMNA (0.52) | CYP3A4MAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL18740349 | 0.74 | PARP1 (0.50) | CYP3A4KDM4EHIF1ACCNE2CDK4 | |
| SCHEMBL28864050 | 0.73 | CYP3A4 (0.74) | CYP3A4MAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL8604208 | 0.71 | MAPT (0.50) | CYP3A4MAPTKDM4ELMNASMN1; SMN2 | |
| Indole SCHEMBL28210661 | 0.71 | CYP3A4 (0.69) | CYP3A4MAPTKDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034158-A1 | METHODS OF TREATING CANCER OF THE CENTRAL NERVOUS SYSTEM COMPRISING 5-ETHYNYL-2'-DEOXYURIDINE | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2026-02-05 | — | — | US | claimed |
| WO-2024020491-A1 | METHODS OF TREATING CANCER OF THE CENTRAL NERVOUS SYSTEM COMPRISING 5-ETHYNYL-2'-DEOXYURIDINE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-01-25 | — | — | WO | claimed |
| EP-3129014-B1 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF AS ANTITUMOUR AGENTS | TETRAHEDRON (FR) | 2021-05-12 | — | — | EP | claimed |
| EP-3515443-A1 | COMBINED COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING A BENZOPHENONE THIAZOLE DERIVATIVES AS A VDA AND TOPOISOMERASE INHIBITOR | Chong Kun Dang Pharmaceutical Corp. (KR) | 2019-07-31 | — | — | EP | claimed |
| US-10308602-B2 | Organoselenium compounds, method for producing same, and pharmaceutical uses thereof in particular as antitumor agents | TETRAHEDRON (FR) | 2019-06-04 | — | — | US | claimed |
| US-9980953-B2 | Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-05-29 | — | — | US | claimed |
| WO-2018056620-A1 | COMBINED COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING A BENZOPHENONE THIAZOLE DERIVATIVES AS A VDA AND TOPOISOMERASE INHIBITOR | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-03-29 | — | — | WO | claimed |
| US-20180085363-A1 | COMBINED COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING A BENZOPHENONE THIAZOLE DERIVATIVES AS A VDA AND TOPOISOMERASE INHIBITOR | NATIONAL CANCER CENTER (KR) | 2018-03-29 | — | — | US | claimed |
| US-20170114011-A1 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF IN PARTICULAR AS ANTITUMOR AGENTS | TETRAHEDRON (FR) | 2017-04-27 | — | — | US | claimed |
| EP-3129014-A2 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF AS ANTITUMOUR AGENTS | Tetrahedron (FR) | 2017-02-15 | — | — | EP | claimed |
| US-20010020038-A1 | Method for inhibiting or treating chemotherapy-induced hair loss | BRISTOL-MYERS SQUIBB COMPANY | 2001-09-06 | — | — | US | claimed |
| EP-0986302-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-03-22 | — | — | EP | claimed |
| WO-1998054966-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1998-12-10 | — | — | WO | claimed |
| EP-0667771-B1 | ANTITUMOUR COMPOSITIONS CONTAINING TAXANE DERIVATIVES | RHONE POULENC RORER SA (FR) | 1998-04-15 | — | — | EP | claimed |
| EP-0667771-A1 | ANTITUMOUR COMPOSITIONS CONTAINING TAXANE DERIVATIVES | Aventis Pharma S.A. (FR) | 1995-08-23 | — | — | EP | claimed |
| WO-1994010995-A1 | ANTITUMOUR COMPOSITIONS CONTAINING TAXANE DERIVATIVES | RHONE-POULENC RORER S.A. (FR) | 1994-05-26 | — | — | WO | claimed |
| EP-0558613-A1 | PYRIDOBENZOINDOLE DERIVATIVES, THEIR PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1993-09-08 | — | — | EP | claimed |
| WO-1992009602-A1 | PYRIDOBENZOINDOLE DERIVATIVES, THEIR PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1992-06-11 | — | — | WO | claimed |
| US-5091388-A | PYRIDOBENZOINDOLE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS WHICH CONTAIN THEM | RHONE-POULENC SANTE (FR) | 1992-02-25 | — | — | US | claimed |
| EP-0402232-A1 | Pyridobenzoindole derivatives, their preparation and compositions containing them | RHONE-POULENC SANTE (FR) | 1990-12-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020038-A1 | Method for inhibiting or treating chemotherapy-induced hair loss | MGMT, TUBB2B, CCAR2 | CYP3A4 2286/4885MAPT 3457/4885KDM4E 960/4885 |
| US-20260034158-A1 | METHODS OF TREATING CANCER OF THE CENTRAL NERVOUS SYSTEM COMPRISING 5-ETHYNYL-2'-DEOXYURIDINE | NSUN2, MKI67, DUT | CYP3A4 4761/4885MAPT 872/4885KDM4E 1027/4885 |
| US-20170114011-A1 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF IN PARTICULAR AS ANTITUMOR AGENTS | SCLY, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC7A5 | CYP3A4 1291/4885MAPT 4699/4885KDM4E 3293/4885 |
| US-10308602-B2 | Organoselenium compounds, method for producing same, and pharmaceutical uses thereof in particular as antitumor agents | SCLY, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT5 | CYP3A4 952/4885MAPT 4575/4885KDM4E 3047/4885 |
| US-20180085363-A1 | COMBINED COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING A BENZOPHENONE THIAZOLE DERIVATIVES AS A VDA AND TOPOISOMERASE INHIBITOR | TOP1, TOP2A, TOP2B | CYP3A4 593/4885MAPT 3546/4885KDM4E 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.